IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-37673-9.html
   My bibliography  Save this article

Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study

Author

Listed:
  • Zhuoying Huang

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Shuangfei Xu

    (Fudan University)

  • Jiechen Liu

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Linlin Wu

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Jing Qiu

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Nan Wang

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Jia Ren

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Zhi Li

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Xiang Guo

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Fangfang Tao

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Jian Chen

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Donglei Lu

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Yuheng Wang

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Juan Li

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Xiaodong Sun

    (Shanghai Municipal Center of Disease Control and Prevention)

  • Weibing Wang

    (Fudan University
    Fudan University
    Fudan University)

Abstract

We conducted a matched retrospective cohort study of two cohorts to estimate inactivated vaccine effectiveness (VE) and its comparative effectiveness of booster dose among older people in Shanghai. Cohort 1 consisted of a vaccinated group (≥1 dose) and an unvaccinated group (3,317,475 pairs), and cohort 2 consisted of a booster vaccinated group and a fully vaccinated group (2,084,721 pairs). The Kaplan–Meier method and Cox regression models were used to estimate risk and hazard ratios (HRs) study outcomes. For cohort 1, the overall estimated VEs of ≥1 dose of inactivated vaccine against SARS-CoV-2 infection, severe/critical Covid-19, and Covid-19 related death were 24.7% (95%CI 23.7%−25.7%), 86.6% (83.1%−89.4%), and 93.2% (88.0%−96.1%), respectively. Subset analysis showed that the booster vaccination provided greatest protection. For cohort 2, compared with full vaccination, relative VEs of booster dose against corresponding outcome were 16.3% (14.4%−17.9%), 60.5% (37.8%−74.9%), and 81.7% (17.5%−95.9%). Here we show, although under the scenario of persistent dynamic zero-Covid policy and non-pharmaceutical interventions, promoting high uptake of the full vaccination series and booster dose among older adults is critically important. Timely vaccination with the booster dose provided effective protection against Covid-19 outcomes.

Suggested Citation

  • Zhuoying Huang & Shuangfei Xu & Jiechen Liu & Linlin Wu & Jing Qiu & Nan Wang & Jia Ren & Zhi Li & Xiang Guo & Fangfang Tao & Jian Chen & Donglei Lu & Yuheng Wang & Juan Li & Xiaodong Sun & Weibing Wa, 2023. "Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37673-9
    DOI: 10.1038/s41467-023-37673-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-37673-9
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-37673-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Huiping Shuai & Jasper Fuk-Woo Chan & Bingjie Hu & Yue Chai & Terrence Tsz-Tai Yuen & Feifei Yin & Xiner Huang & Chaemin Yoon & Jing-Chu Hu & Huan Liu & Jialu Shi & Yuanchen Liu & Tianrenzheng Zhu & J, 2022. "Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron," Nature, Nature, vol. 603(7902), pages 693-699, March.
    2. Julia Stowe & Nick Andrews & Freja Kirsebom & Mary Ramsay & Jamie Lopez Bernal, 2022. "Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    3. Peter J. Halfmann & Shun Iida & Kiyoko Iwatsuki-Horimoto & Tadashi Maemura & Maki Kiso & Suzanne M. Scheaffer & Tamarand L. Darling & Astha Joshi & Samantha Loeber & Gagandeep Singh & Stephanie L. Fos, 2022. "SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters," Nature, Nature, vol. 603(7902), pages 687-692, March.
    4. Otavio T. Ranzani & Matt D. T. Hitchings & Rosana Leite Melo & Giovanny V. A. França & Cássia de Fátima R. Fernandes & Margaret L. Lind & Mario Sergio Scaramuzzini Torres & Daniel Henrique Tsuha & Let, 2022. "Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Taha Y. Taha & Irene P. Chen & Jennifer M. Hayashi & Takako Tabata & Keith Walcott & Gabriella R. Kimmerly & Abdullah M. Syed & Alison Ciling & Rahul K. Suryawanshi & Hannah S. Martin & Bryan H. Bach , 2023. "Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    2. Bruno A. Rodriguez-Rodriguez & Grace O. Ciabattoni & Ralf Duerr & Ana M. Valero-Jimenez & Stephen T. Yeung & Keaton M. Crosse & Austin R. Schinlever & Lucie Bernard-Raichon & Joaquin Rodriguez Galvan , 2023. "A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    3. Mingxi Li & Yifei Ren & Zhen Qin Aw & Bo Chen & Ziqing Yang & Yuqing Lei & Lin Cheng & Qingtai Liang & Junxian Hong & Yiling Yang & Jing Chen & Yi Hao Wong & Jing Wei & Sisi Shan & Senyan Zhang & Jiwa, 2022. "Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    4. Naoko Iwata-Yoshikawa & Masatoshi Kakizaki & Nozomi Shiwa-Sudo & Takashi Okura & Maino Tahara & Shuetsu Fukushi & Ken Maeda & Miyuki Kawase & Hideki Asanuma & Yuriko Tomita & Ikuyo Takayama & Shutoku , 2022. "Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    5. Guoli Shi & Tiansheng Li & Kin Kui Lai & Reed F. Johnson & Jonathan W. Yewdell & Alex A. Compton, 2024. "Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    6. Ankita Leekha & Arash Saeedi & Monish Kumar & K. M. Samiur Rahman Sefat & Melisa Martinez-Paniagua & Hui Meng & Mohsen Fathi & Rohan Kulkarni & Kate Reichel & Sujit Biswas & Daphne Tsitoura & Xinli Li, 2024. "An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models," Nature Communications, Nature, vol. 15(1), pages 1-21, December.
    7. Neeltje van Doremalen & Jonathan E. Schulz & Danielle R. Adney & Taylor A. Saturday & Robert J. Fischer & Claude Kwe Yinda & Nazia Thakur & Joseph Newman & Marta Ulaszewska & Sandra Belij-Rammerstorfe, 2022. "ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    8. Yin-Feng Kang & Cong Sun & Jing Sun & Chu Xie & Zhen Zhuang & Hui-Qin Xu & Zheng Liu & Yi-Hao Liu & Sui Peng & Run-Yu Yuan & Jin-Cun Zhao & Mu-Sheng Zeng, 2022. "Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    9. Leire Campos-Mata & Benjamin Trinité & Andrea Modrego & Sonia Tejedor Vaquero & Edwards Pradenas & Anna Pons-Grífols & Natalia Rodrigo Melero & Diego Carlero & Silvia Marfil & César Santiago & Dàlia R, 2024. "A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    10. Sapna Sharma & Thomas Vercruysse & Lorena Sanchez-Felipe & Winnie Kerstens & Madina Rasulova & Lindsey Bervoets & Carolien Keyzer & Rana Abdelnabi & Caroline S. Foo & Viktor Lemmens & Dominique Loover, 2022. "Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    11. Zhennan Zhao & Yufeng Xie & Bin Bai & Chunliang Luo & Jingya Zhou & Weiwei Li & Yumin Meng & Linjie Li & Dedong Li & Xiaomei Li & Xiaoxiong Li & Xiaoyun Wang & Junqing Sun & Zepeng Xu & Yeping Sun & W, 2023. "Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    12. Xiaolei Wang & Terrence Tsz-Tai Yuen & Ying Dou & Jingchu Hu & Renhao Li & Zheng Zeng & Xuansheng Lin & Huarui Gong & Celia Hoi-Ching Chan & Chaemin Yoon & Huiping Shuai & Deborah Tip-Yin Ho & Ivan Fa, 2023. "Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    13. Denis Mongin & Nils Bürgisser & Gustavo Laurie & Guillaume Schimmel & Diem-Lan Vu & Stephane Cullati & Delphine Sophie Courvoisier, 2023. "Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    14. Tomokazu Tamura & Jumpei Ito & Keiya Uriu & Jiri Zahradnik & Izumi Kida & Yuki Anraku & Hesham Nasser & Maya Shofa & Yoshitaka Oda & Spyros Lytras & Naganori Nao & Yukari Itakura & Sayaka Deguchi & Ri, 2023. "Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
    15. James Brett Case & Samantha Mackin & John M. Errico & Zhenlu Chong & Emily A. Madden & Bradley Whitener & Barbara Guarino & Michael A. Schmid & Kim Rosenthal & Kuishu Ren & Ha V. Dang & Gyorgy Snell &, 2022. "Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    16. Lays Cordeiro Guimaraes & Pedro Augusto Carvalho Costa & Sérgio Ricardo Aluotto Scalzo Júnior & Heloísa Athaydes Seabra Ferreira & Ana Carolina Soares Braga & Leonardo Camilo Oliveira & Maria Marta Fi, 2024. "Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    17. Chun-Kit Yuen & Wan-Man Wong & Long-Fung Mak & Joy-Yan Lam & Lok-Yi Cheung & Derek Tsz-Yin Cheung & Yau-Yee Ng & Andrew Chak-Yiu Lee & Nanshan Zhong & Kwok-Yung Yuen & Kin-Hang Kok, 2023. "An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    18. Hung Fu Tseng & Bradley K. Ackerson & Katia J. Bruxvoort & Lina S. Sy & Julia E. Tubert & Gina S. Lee & Jennifer H. Ku & Ana Florea & Yi Luo & Sijia Qiu & Soon Kyu Choi & Harpreet S. Takhar & Michael , 2023. "Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    19. Srikanth Sadhu & Rajdeep Dalal & Jyotsna Dandotiya & Akshay Binayke & Virendra Singh & Manas Ranjan Tripathy & Vinayaka Das & Sandeep Goswami & Shakti Kumar & Zaigham Abbas Rizvi & Amit Awasthi, 2023. "IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammation," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    20. Cai He & Jingyun Yang & Weiqi Hong & Zimin Chen & Dandan Peng & Hong Lei & Aqu Alu & Xuemei He & Zhenfei Bi & Xiaohua Jiang & Guowen Jia & Yun Yang & Yanan Zhou & Wenhai Yu & Cong Tang & Qing Huang & , 2022. "A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant," Nature Communications, Nature, vol. 13(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37673-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.